CC BY-NC-ND 4.0 · South Asian J Cancer 2020; 09(04): 195-198
DOI: 10.1055/s-0041-1728225
Original Article: Head and Neck Cancer

Chemoradiation in Unresectable Oral Cavity Cancer: A Myth or Reality!

Vijay Maruti Patil
1  Department of Medical Oncology, HBNI, Tata Memorial Hospital, Mumbai, Maharashtra, India
,
Vanita Noronha
1  Department of Medical Oncology, HBNI, Tata Memorial Hospital, Mumbai, Maharashtra, India
,
Amit Joshi
1  Department of Medical Oncology, HBNI, Tata Memorial Hospital, Mumbai, Maharashtra, India
,
Amit Kumar
1  Department of Medical Oncology, HBNI, Tata Memorial Hospital, Mumbai, Maharashtra, India
,
Hollis Dsouza
1  Department of Medical Oncology, HBNI, Tata Memorial Hospital, Mumbai, Maharashtra, India
,
Atanu Bhattacharjee
2  Department of Epidemiology, Advanced Centre for Treatment, Research and Education in Cancer, Navi Mumbai, Maharashtra, India
,
Abhishek Mahajan
1  Department of Medical Oncology, HBNI, Tata Memorial Hospital, Mumbai, Maharashtra, India
,
Nilesh Sabale
1  Department of Medical Oncology, HBNI, Tata Memorial Hospital, Mumbai, Maharashtra, India
,
Sarbani Ghosh-Laskar
3  Department of Radiation Oncology, HBNI, Tata Memorial Hospital, Mumbai, Maharashtra, India
,
Kumar Prabhash
1  Department of Medical Oncology, HBNI, Tata Memorial Hospital, Mumbai, Maharashtra, India
› Author Affiliations
Funding N. reports research grants from Dr. Reddy’s Laboratories Inc, Amgen, Sanofi India Ltd., Intas Pharmaceuticals and Astra Zeneca Pharma India Ltd., outside the submitted work. K.P. reports grants from Biocon Ltd, grants from Dr. Reddy’s Laboratories Inc, grants from Fresenius Kabi India Pvt Ltd, grants from Alkem Laboratories, grants from Natco Pharma Ltd, grants from BDR Pharmaceuticals Intl Pvt Ltd, grants from Roche Holding AG, outside the submitted work. All grants were paid to the institution.

Abstract

Objective Earlier studies have shown that chemoradiation (CTRT) has benefits in the head-and-neck cancer, but how far it is true for oral cavity subset that has not been exactly explored. Keeping the null hypothesis as CTRT has no benefit in oral cavity cancer, we studied the outcome of patients undergoing chemoradiation in unresectable oral cavity cancers. The aim of this study is to study whether overall survival (OS) increases with chemoradiation in unresectable oral cavity cancers.

Patients and Methods Between December 2014 and February 2017, 23 patients aged 18 years and above were planned chemoradiation for unresectable oral cavity cancer and were included for this analysis.

Results The median age of patients was 43 years and all patients were addicted to tobacco. In total, 12 of 23 (52%) completed CTRT. One patient (1/23) was alive at the time of final analysis with median OS of 5.83 (2.73–9.60) months. The median progression free survival and OS in patients who completed chemoradiation were 6.42 months (95% confidence interval [CI]: 3.67–10.53) and 8.9 months (95% CI: 4.4–23.07), respectively.

Conclusion CTRT has a limited role in unresectable oral cancers.



Publication History

Publication Date:
12 June 2021 (online)

© 2021. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical and Scientific Publishers Private Ltd
A-12, Second Floor, Sector -2, NOIDA -201301, India